Table: Sumitomo Pharma -6-MTH group results (IFRS)

Sumitomo Pharma

31/10/2023 04:30

Oct 31 (Reuters)- 
              Sumitomo Pharma Co., Ltd. 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                 6 months ended      6 months ended        Year to   
                Sep 30, 2023        Sep 30, 2022       Mar 31, 2024  
                   LATEST             YEAR-AGO           COMPANY     
                   RESULTS             RESULT            FORECAST    
  Sales            152.64              319.29             362.00     
                 (-52.2 pct)         (+8.7 pct)        (-34.8 pct)   
  Operating      loss 86.50          loss 28.92         loss 78.00   
  Pretax
  Net            loss 67.74           loss 7.28         loss 80.00   
  EPS Basic    loss 170.51 yen     loss 18.33 yen    loss 201.36 yen 
  Ann Div                             21.00 yen            NIL       
  -Q2 Div            NIL              14.00 yen                      
  -Q4 Div                             7.00 yen             NIL       
 
  NOTE - Sumitomo Pharma Co., Ltd.. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4506.T